Since the beginning of the vaccine rollout to 31 October 2021, about 35.7 million doses of COVID-19 vaccines have been administered.
21.9 million - Comirnaty (Pfizer)
678,000 - Spikevax (Moderna)Â
13.1 million - Vaxzevria (AstraZeneca)Â
To 31 October 2021, we have received 1411 reports after vaccination with Comirnaty (Pfizer) and Spikevax (Moderna) of people aged under 18 years
The TGA has found 9 reports of death that were linked to immunisation from 642 reports received and reviewed (overwhelming majority over 65). Of the deaths caused by vaccination, 8 were TTS cases and one was a case of immune thrombocytopenia (ITP).
*Minor variations to figures as the adverse events were captured from the database of Adverse Event Notifications up to October 21.
ADVERSE EVENTS REPORTED BY THE TGA
Myocarditis / Pericarditis
Risk: 1/14,925 - 1/100,000
To 31 October 2021, the TGA has received 253 reports which have been assessed as likely to be myocarditis (Pfizer +18 cases this past week).
There have also been 1085 reported cases of pericarditis.
* the youngest myocarditis case is of a 12 year old boy
Around half of the patients were admitted to hospital with 8 being treated in intensive care. Most patients treated in hospital were discharged within 4 days.Â
TTS (Clots with low platelets)
Risk: 1/50,000
One new case of TTS was reported this week, taking the total to 158 cases from about 13.1 million doses of Vaxzevria (AstraZeneca).
Overall Status
Guillain-Barre Syndrome
Risk: 1/100,000
To 31 October 2021, the TGA has received 141 reports of suspected GBS occurring after vaccination with Vaxzevria (AstraZeneca).
Immune Thrombocytopenia (ITP)
Risk: 1/40,000 to 1 / 100,000
To 31 October 2021, the TGA has received 87 reports of suspected ITP following vaccination with Vaxzevria (AstraZeneca).
ATAGI UPDATES
Vaccinating Children
ATAGI has previously noted the TGA’s registration of Pfizer and Moderna for use in children from 12 years of age and supports COVID-19 vaccination in all adolescents from 12 years of age.
Boosters
ATAGI recommendations on the use of a booster dose of COVID-19 vaccine It is expected up to approximately 500,000 people in Australia who are severely immunocompromised may need a third dose of vaccine over the coming months. Recommendations
ATAGI advises that, based on current evidence, the highest priority groups to receive booster doses are those with risk factors for severe COVID-19 and/or those at increased occupational risk of COVID-19, notably:
People at greater risk of severe COVID-19: individuals aged 50 years and older, those with underlying medical conditions, residents of aged care and disability facilities, and Aboriginal and Torres Strait Islander adults.
People at increased occupational risk of COVID-19:in these individuals due to prior vaccination and younger age
ATAGI also notes the announcement of a booster program using the Pfizer vaccine for those who completed their primary course of COVID-19 vaccines 6 or more months ago.
VACCINE HESITANCY MONITORING
VACCINATIONS BY STATE
1 in 4 people from QLD, WA, & NT have NOT had their first COVID-19 vaccine dose!!
SA is not very far in front at only 77.7% receiving their first dose.
VACCINATIONS BY AGE GROUP
